Department of Obstetrics and Gynecology, Otto-von-Guericke University, Magdeburg, Germany.
Am J Obstet Gynecol. 2010 Dec;203(6):595.e9-16. doi: 10.1016/j.ajog.2010.07.034. Epub 2010 Oct 20.
This study was undertaken to evaluate the potential role of G-protein-coupled estrogen receptor in endometrial pathology associated with tamoxifen treatment of breast cancer patients.
We investigated whether G-protein-coupled estrogen receptor plays a role in mediating proliferating effect of tamoxifen in endometrial carcinoma cells. These results were compared with the G-protein-coupled estrogen receptor expression pattern in endometrial tissue from a cohort of 95 breast cancer patients, who received tamoxifen or another adjuvant therapy.
In vitro tamoxifen significantly stimulated the mitogen-activated protein kinase phosphorylation and cell proliferation of endometrial cell lines via G-protein-coupled estrogen receptor. In vivo, there was a significant correlation between G-protein-coupled estrogen receptor expression and the tamoxifen-induced endometrial pathology (P = .006). Moreover, G-protein-coupled estrogen receptor positivity was predictive of an earlier development of symptoms, such as bleeding or suspect endometrial thickness, induced by tamoxifen therapy (P = .019).
G-protein-coupled estrogen receptor plays an important role in tamoxifen-induced endometrial abnormalities.
本研究旨在评估 G 蛋白偶联雌激素受体在与乳腺癌患者接受他莫昔芬治疗相关的子宫内膜病理中的潜在作用。
我们研究了 G 蛋白偶联雌激素受体是否在介导他莫昔芬对子宫内膜癌细胞的增殖作用中发挥作用。这些结果与 95 例接受他莫昔芬或其他辅助治疗的乳腺癌患者的子宫内膜组织中 G 蛋白偶联雌激素受体表达模式进行了比较。
体外他莫昔芬通过 G 蛋白偶联雌激素受体显著刺激了子宫内膜细胞系的丝裂原激活蛋白激酶磷酸化和细胞增殖。体内，G 蛋白偶联雌激素受体的表达与他莫昔芬引起的子宫内膜病变之间存在显著相关性（P =.006）。此外，G 蛋白偶联雌激素受体阳性预测了他莫昔芬治疗引起的症状（如出血或可疑的子宫内膜增厚）更早出现（P =.019）。
G 蛋白偶联雌激素受体在他莫昔芬诱导的子宫内膜异常中发挥重要作用。
